In addition, recent in vitro and in vivo experiments have shown that cisplatin can enhance tumor immunogenicity by increasing MHC I cell surface expression, but, at the same time, it can induce up-regulation of PD-L1 in human and mouse ovarian cancer cell lines (64). Here, CD274 is linked to ovarian cancer.